Prostate cancer is the second most common cancer among men. Globally, 1 in 8 men will face this potentially deadly diagnosis at some point in their lives. At Oxford BioDynamics, we understand the importance of early detection. That’s why we’ve developed the EpiSwitch PSE, our groundbreaking 94% accurate prostate screening test. Awareness plays a crucial role in catching cancer early. By promoting knowledge and encouraging regular screenings, many lives can be extended or even saved.
This Movember, we invite you—our partners, collaborators, clinical providers, friends, and family—to join us in supporting Zero Prostate Cancer's #GrowAndGive campaign. Help us raise awareness by growing a beard or wearing boldly blue styles, and consider donating to help fund novel research and progressive patient support programs.
For every dollar you contribute during this campaign, we’ll match up to a total of $5,000. Together, let’s work to zero out prostate cancer.
Learn more about our 94% accurate prostate screening test at 94percent.com.